VolitionRx highlights $5 million feline paper milestone in corporate deck
VNRX•Sepsis program targeted for 2026 launch
The government-backed DETECSEPS sepsis program in France, financed at about USD 7.3 million, is targeted for a Q3 2026 launch.
Feline paper milestone and product updates
VolitionRx flagged a potential USD 5 million contractual milestone tied to publication of a feline lymphoma manuscript.
Nu.Q Vet canine cancer screening launched on the IDS i10 automated analyzer via Fujifilm Vet Systems.
Corporate deck highlights licensing strategy and revenue
VolitionRx outlined an asset-light strategy focused on licensing Nu.Q technology across cancer, sepsis, and veterinary diagnostics.
The company reported USD 23 million in licensing and USD 1.4 million revenue in H1 2026.
